Cancer cells exhibit altered activity of various metabolic enzymes and pathways. Key enzymes such as Hexokinase 2 and Pyruvate kinase M2 are often upregulated, enhancing glycolytic flux. Moreover, oncogenes like MYC and RAS can drive metabolic reprogramming by increasing the expression of genes involved in glucose uptake and metabolism.
